Power3, New Horizons Sign Diagnostic Research Agreement

March 29, 2005

Power3 Medical Products has entered into a collaborative research agreement with New Horizons Diagnostics for the development of antibody-based diagnostic tests for neurodegenerative disease using the company's identified protein biomarkers.

Power3 intends to develop a series of tests that involve monitoring the concentration of panels of proteins in the blood. Power3 has discovered unique groups of biomarkers whose profiles are relatively sensitive and specific in distinguishing patients with amyotrophic lateral sclerosis, Alzheimer's disease and Parkinson's disease from each other, as well as from normal patients and patients with other neuromuscular and neurological disorders.

New Horizons Diagnostics will use specifically tailored monoclonal and polyclonal antibodies to the biomarkers, which will be incorporated into immunoassays. Once the assays are available, New Horizons Diagnostics will then develop and validate diagnostic tests on their platform, specifically designed to detect and discriminate among the neurodegenerative diseases.